Carbohydrate-based Cancer Vaccines: Target Cancer with Sugar Bullets

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 2012 Jun 7

PMID 22669462

Citations 21

Authors

Chang-Cheng Liu

Xin-Shan Ye

Affiliations

Soon will be listed here.

Abstract

With the booming development of glycobiology and glycochemistry, more and more structures of tumor-associated carbohydrate antigens (TACAs) are identified. Their broad expression and high specificity in cancer make them important targets to develop cancer vaccines or immunotherapies. However, most of the TACAs are T cell-independent antigens, they cannot elicit a powerful enough immune response to prevent or treat cancer. Immunotolerance and immunosuppression are more easily induced due to their endogenous properties and the declining immunity of the patients. This review summarizes the recent efforts to overcome these obstacles: coupling the carbohydrate antigens to proper carriers such as proteins or some small molecule carriers, and chemically modifying the structures of the TACAs to enhance the immunogenicity of TACAs and break the immunotolerance.

Citing Articles

Isolipoic acid-linked gold nanoparticles bearing the thomsen friedenreich tumor-associated carbohydrate antigen: Stability and studies.

Mondal U, Barchi Jr J Front Chem. 2022; 10:1002146.

PMID: 36300019 PMC: 9588967. DOI: 10.3389/fchem.2022.1002146.

Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments.

Shivatare S, Shivatare V, Wong C Chem Rev. 2022; 122(20):15603-15671.

PMID: 36174107 PMC: 9674437. DOI: 10.1021/acs.chemrev.1c01032.

A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens.

Trabbic K, Kleski K, Barchi Jr J ACS Bio Med Chem Au. 2021; 1(1):31-43.

PMID: 34927166 PMC: 8675876. DOI: 10.1021/acsbiomedchemau.1c00021.

Synthesis and immunological evaluation of -acyl modified Globo H derivatives as anticancer vaccine candidates.

Zhai C, Zheng X, Song C, Ye X RSC Med Chem. 2021; 12(7):1239-1243.

PMID: 34355188 PMC: 8292959. DOI: 10.1039/d1md00067e.

Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.

Zhao Y, Li S, Lv J, Liu Y, Chen Y, Liu Y Theranostics. 2021; 11(15):7425-7438.

PMID: 34158858 PMC: 8210591. DOI: 10.7150/thno.60211.

References

He L, Crocker A, Lee J, Mendoza-Ramirez J, Wang X, Vitale L . Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol. 2007; 178(10):6259-67. DOI: 10.4049/jimmunol.178.10.6259. View

Barington T, Gyhrs A, Kristensen K, Heilmann C . Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1994; 62(1):9-14. PMC: 186060. DOI: 10.1128/iai.62.1.9-14.1994. View

Zou W, Borrelli S, Gilbert M, Liu T, Pon R, Jennings H . Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J Biol Chem. 2004; 279(24):25390-9. DOI: 10.1074/jbc.M402787200. View

Ragupathi G, Livingston P, Hood C, Gathuru J, Krown S, Chapman P . Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003; 9(14):5214-20. View

Alexander J, del Guercio M, Maewal A, Qiao L, Fikes J, Chesnut R . Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 2000; 164(3):1625-33. DOI: 10.4049/jimmunol.164.3.1625. View

Ragupathi G, Coltart D, Williams L, Koide F, Kagan E, Allen J . On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc Natl Acad Sci U S A. 2002; 99(21):13699-704. PMC: 129747. DOI: 10.1073/pnas.202427599. View

Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W . A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother. 2003; 52(10):608-16. PMC: 11041859. DOI: 10.1007/s00262-003-0399-2. View

Kudryashov V, Glunz P, Williams L, Hintermann S, Danishefsky S, LLOYD K . Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc Natl Acad Sci U S A. 2001; 98(6):3264-9. PMC: 30642. DOI: 10.1073/pnas.051623598. View

Sanders D, Kerr M . Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours. Mol Pathol. 2000; 52(4):174-8. PMC: 395696. DOI: 10.1136/mp.52.4.174. View

10.

Bundle D, Rich J, Jacques S, Yu H, Nitz M, Ling C . Thiooligosaccharide conjugate vaccines evoke antibodies specific for native antigens. Angew Chem Int Ed Engl. 2005; 44(47):7725-9. DOI: 10.1002/anie.200502179. View

11.

De Silva R, Wang Q, Chidley T, Appulage D, Andreana P . Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J Am Chem Soc. 2009; 131(28):9622-3. DOI: 10.1021/ja902607a. View

12.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

13.

Dalgleish A . Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine. 2011; 29(47):8501-5. DOI: 10.1016/j.vaccine.2011.09.012. View

14.

Kaiser A, Gaidzik N, Westerlind U, Kowalczyk D, Hobel A, Schmitt E . A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew Chem Int Ed Engl. 2009; 48(41):7551-5. DOI: 10.1002/anie.200902564. View

15.

Zipfel P, Skerka C . Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009; 9(10):729-40. DOI: 10.1038/nri2620. View

16.

De Silva R, Appulage D, Pietraszkiewicz H, Bobbitt K, Media J, Shaw J . The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17. Cancer Immunol Immunother. 2012; 61(4):581-5. PMC: 3417815. DOI: 10.1007/s00262-012-1205-9. View

17.

Morel P, Turner M . Designing the optimal vaccine: the importance of cytokines and dendritic cells. Open Vaccine J. 2011; 3:7-17. PMC: 3149857. DOI: 10.2174/1875035401003010007. View

18.

Wu J, Guo Z . Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Bioconjug Chem. 2006; 17(6):1537-44. PMC: 2532825. DOI: 10.1021/bc060103s. View

19.

Caspi R . Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008; 8(12):970-6. PMC: 2764117. DOI: 10.1038/nri2438. View

20.

Duan J, Avci F, Kasper D . Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc Natl Acad Sci U S A. 2008; 105(13):5183-8. PMC: 2278222. DOI: 10.1073/pnas.0800974105. View